MedPath

Prevalence Rates of USI, BO, DO and Their Clinical and Urodynamic Findings in Women With ≥Stage II Cystocele

Completed
Conditions
Lower Urinary Tract Symptom in Severe Cystocele Women
Registration Number
NCT03613350
Lead Sponsor
National Taiwan University Hospital
Brief Summary

Prevalence rates of urodynamic stress incontinence (USI), bladder oversensitivity (BO) /detrusor overactivity (DO) or both and their related clinical and urodynamic findings in women with ≥ pelvic organ prolapse quantification stage II cystocele are important for clinical consultation. Thus, the aim of this study was to elucidate the above findings and between-group associations.

Detailed Description

Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. ANOVA test and post-hoc testing with bonferroni's correction were used for statistical analysis. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction. BO was defined as \<300 mL of the volume at strong desire to void during filling cystometry. Those women without USI, BO or DO were allocated into the no demonstrated USI+BO/DO group.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
480
Inclusion Criteria
  1. Age >20y/o
  2. Severe cystocele, ie, more than stage 2
  3. Complete pad test and urodynamic study
Exclusion Criteria
  1. Pregnancy
  2. Urinary tract infection
  3. Had received pelvic reconstruction

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
USIBetween November 2011 and January 2017

Urodynamic stress incontinence was noted during examination

BO/DOBetween November 2011 and January 2017

Bladder oversensitivity/detrusor overactivity was noted during examination

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.